Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 .
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17 months
Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix (asciminib) vs. Bosulif (bosutinib) and lower discontinuation rate due to adverse
/PRNewswire/ Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular.
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up